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Abstract
Introduction: Non-Hodgkin’s lymphoma (NHL) is the sixth most common malignancy, and follicular lymphoma (FL) is the second most
common form of NHL. FL is generally considered to be incurable, and is characterized by periods of remission followed by episodes of
relapse, with median survival of 8–10 years. Maintenance treatment is aimed at improving quality of life and survival.
Aims: To review the current evidence for maintenance rituximab in patients with FL.
Evidence review: Two randomized studies of rituximab maintenance or observation after induction therapy with single-agent rituximab,
which were performed mainly in patients with relapsed/refractory disease, have demonstrated a two- to three-fold improvement in
median progression-free survival (PFS) in the maintenance arm. Two further studies of rituximab maintenance or observation following
induction chemotherapy with or without rituximab performed in patients with relapsed/refractory FL have shown a two- to four-fold
increase in median PFS in the maintenance arm. In one of these studies an overall survival benefit has also been demonstrated. An
additional study, this time in previously untreated patients, has demonstrated a four-fold improvement in median PFS as well as a
significant overall survival benefit with rituximab maintenance following induction with chemotherapy alone.
Place in therapy: Currently rituximab maintenance can be considered to be appropriate therapy for patients with relapsed/refractory
disease who have not received rituximab previously and who are not suitable for autologous stem cell transplantation, and for patients
who receive first-line therapy with chemotherapy without rituximab.
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Core evidence place in therapy summary for rituximab as maintenance therapy in relapsed or
refractory non-Hodgkin’s lymphoma
Outcome measure Evidence Implications
Patient-oriented evidence
Rituximab maintenance prolongs PFS substantially in patients
with relapsed/refractory FL who are rituximab naïve and respond
to reinduction therapy
Clear Rituximab maintenance improves PFS by approximately two- to three-fold
Rituximab maintenance significantly improves EFS in previously
untreated patients who receive single-agent rituximab as
induction therapy
Substantial EFS increased from 19 to 36 months
Rituximab maintenance improves overall survival in a group of
patients with relapsed/refractory FL who are rituximab naïve 
and respond to reinduction with CHOP chemotherapy with or
without rituximab 
Moderate Rituximab maintenance reduces the risk of dying by approximately one-third
at 3 years
In patients with relapsed/refractory FL, re-treatment with
rituximab at disease progression may confer a similar period of
rituximab benefit as rituximab maintenance
Moderate Re-treatment strategy may be less costly but needs verification. RESORT
trial ongoing
Rituximab maintenance is beneficial in patients with relapsed/
refractory FL who have been exposed to prior rituximab
None
Rituximab maintenance is beneficial in previously untreated
patients with FL who receive chemotherapy and rituximab as
induction therapy
None PRIMA study ongoing
Rituximab maintenance results in an improvement in 
patients’ quality of life
None
continued overleaf...Scope, aims, and objectives
The aim of this article is to review the evidence for the use of
rituximab (MabThera®, F. Hoffmann-La Roche) as maintenance
therapy and to determine its place in therapy in the management
of patients with relapsed or refractory follicular lymphoma (FL).
Methods
English language literature searches were conducted on 
January 24, 2007 in the following databases, searching from the
beginning of the database to date unless otherwise stated. The
search strategy was “rituximab AND low grade lymphoma” unless
otherwise stated:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966
to date. Limits imposed “English,” “clinical trial,” “meta
analysis,” “randomized controlled trial,” “human,” for specificity
• EMBASE, http://www.datastarweb.com, 1974 to date. Search
term “(rituximab AND low grade lymphoma) AND (LG=EN) AND
((HUMAN=YES))”
• BIOSIS, http://www.datastarweb.com. Search term “(rituximab
AND low grade lymphoma) AND (LG=EN) AND ((HUMANS#))” 
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluations Database
(NHSEED), Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/crddatabases.htm. All three
databases searched together. All fields searched
• NHS HTA, http://www.ncchta.org
• National Guideline Clearinghouse, http://www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm. Entire site searched
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• Clinical trials databases, http://www.clinicaltrials.gov, and
http://www.clinicalstudyresults.org
Online abstracts from the American Society of Hematology 2005
and 2006 annual meetings were searched using the search terms
“rituximab,” “indolent NHL,” or “cost effectiveness.” Only articles
directly related to rituximab maintenance were included. Following
removal of out-of-scope articles, one paper was included.
Searching using the terms “follicular” or “indolent lymphoma”
identified a further eight papers and four abstracts (Table 1).
Disease overview
Non-Hodgkin’s lymphoma (NHL) is the sixth most common
malignancy in men and women accounting for 4% and 3%,
respectively, of all new diagnoses of cancer in the UK (Cancer
Research UK 2007). FL is the second most common form of NHL
accounting for 22% of NHL in adults (Armitage & Weisenburger
1998). Its incidence has been increasing over the past few
decades by approximately 3% per year, but more recently the
incidence has stabilized (Morton et al. 2006). FL is generally
considered to be an incurable illness. It is characterized by
periods of remission followed by episodes of relapse until,
ultimately, the disease becomes resistant to therapy and death
due to progressive disease ensues. The median survival of
patients with advanced disease in the pre-rituximab era was 
8–10 years. There is evidence that this has improved since the
incorporation of rituximab into treatment regimens (Fisher et al.
2005; Swenson et al. 2005). The therapeutic strategy is to control
the disease when necessary with the aim of maximizing the
patients’ quality of life as well possibly improving survival. 
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Category Number of records
Full papers Abstracts
Initial search 948 1
records excluded 93 81
records included 1 0
Additional studies identified 8 4
Total records included 9 4
Level 1 clinical evidence
(systematic review, meta analysis)
00
Level 2 clinical evidence (RCT) 4 1
Level ≥3 clinical evidence 5 1
trials other than RCT 5 1
case reports 00
Economic evidence 0 2
For definitions of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review 
...table continued
Outcome measure  Evidence Implications
Economic evidence
Rituximab maintenance in relapsed/refractory patients is cost
effective compared with autograft
Limited
Rituximab maintenance is cost effective compared with
observation alone
Limited Estimated cost of 1 quality-adjusted life-year is £8910
CHOP, cyclophosphamide, vincristine, prednisone, doxorubicin; EFS, event-free survival; FL, follicular lymphoma; PFS, progression-free survival.123
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Current therapy options
Asymptomatic patients with advanced disease who have
reasonable bone marrow function can often be managed
expectantly for a median of 2.5 years before systemic therapy is
required. This “watch and wait” approach has been shown to be
no worse than starting immediate systemic therapy with regards
to survival, and is generally thought to result in a better quality of
life by avoiding the side effects of chemotherapy (Ardeshna et al.
2003). When patients become symptomatic due to disease
progression, systemic therapy is required. Prior to the
introduction of rituximab, the choice of therapy included
monotherapy with alkylating agents (e.g. chlorambucil or
cyclophosphamide), multiagent chemotherapy with or without
anthracyclines [e.g. CVP (cyclophosphamide, vincristine,
prednisone), CHOP (cyclophosphamide, vincristine, prednisone,
doxorubicin)], and purine analogs (e.g. fludarabine), either alone
or in combination with alkylating agents ± anthracycline. When
patients relapse the same therapy is often used again if the
duration of response is more than 2 years and there are no dose-
limiting considerations (e.g. maximum tolerated anthracycline
dose), otherwise an alternative treatment is used. In some
countries such as France, interferon alfa in induction or
maintenance therapy is standard. Consolidation of second or
subsequent remission with autologous stem cell transplantation
(ASCT) has been shown to be superior to observation in terms of
progression-free survival (PFS) and overall survival (OS) in a small,
multicenter, randomized trial (Schouten et al. 2003) and is
standard practice in some centers. Allogeneic stem cell
transplantation appears to have curative potential but with
significant risk limiting its use to selected younger patients (van
Besien et al. 2003). Radiotherapy is very useful for the treatment
of symptomatic nodes. 
With the introduction of rituximab, therapeutic options have been
considerably widened. Rituximab is a humanized, chimeric,
monoclonal antibody directed against CD20. CD20 is a molecule
expressed on normal and malignant B cells but not expressed on
stem cells or plasma cells. CD20 is not internalized or shed and
appears to be an ideal target for immunotherapy. Rituximab
binding to CD20 results in cell death via several mechanisms,
namely antibody-dependent cell-mediated cytotoxicity,
complement-mediated cell lysis, and direct triggering of
apoptosis by activation of intracellular signal transduction
pathways. The specificity of rituximab accounts for its lack 
of toxicity.
In a pivotal trial, four doses of rituximab 375 mg/m2 per week
were administered to 166 patients with relapsed or refractory
indolent lymphoma, including 130 patients with follicular
lymphoma (McLaughlin et al. 1998). The response rate was 48%
(60% for patients with FL), and the median time to progression
was 13 months. Toxicity was minimal and largely consisted of
National Cancer Institute (NCI) grade 1 and 2 infusion-related 
side effects. 
In another study, 49 patients with previously untreated, low tumor
burden FL received this standard induction with rituximab 
(four weekly doses of rituximab 375 mg/m2) (McLaughlin et al.
1998). This trial has recently been updated after 7 years’ follow-
up (Colombat et al. 2006). The overall best response rate was
74% [complete remission (CR) 50%; partial remission (PR) 24%].
The median PFS was 23.5 months with a median response
duration of 28.6 months. A total of 24% of responders maintained
their response at 5 years and 15% at 7 years without any 
further therapy. 
Several phase III studies have shown that the addition of
rituximab to induction chemotherapy (in relapsed and previously
untreated patients) significantly improves PFS and in some cases
an OS benefit has been demonstrated without a clinically
significant increase in toxicity (Herold et al. 2004; Salles et al.
2004; Hiddemann et al. 2005; Marcus et al. 2005; Forstpointner et
al. 2006; van Oers et al. 2006). 
Unmet needs
Lymphoma cells that persist after induction therapy are
responsible for subsequent relapse. Reduction in the numbers of
these cells may result in prolongation of remissions. This
reduction can be attempted by the administration of further
consolidation therapy or by using a maintenance strategy.
Consolidation therapy (e.g. high-dose therapy followed by ASCT)
is aimed at eliminating as much residual disease as possible.
Maintenance therapy on the other hand is administered in 
regular doses over a prolonged period of time to prevent 
the reestablishment of malignant cells and thereby prolong the
time until relapse (Berinstein 2006). Maintenance therapy in 
FL is aimed at maximizing the patient’s quality of life as well 
as improving survival. In order to achieve this, maintenance
therapy should be convenient, nontoxic, and efficacious. As 
a maintenance therapy interferon alfa is inconvenient as it 
requires injections 3 times a week. It has significant side 
effects requiring temporary or permanent cessation of 
treatment, and in a meta analysis was found to be ineffective
when administered as maintenance therapy (Rohatiner et 
al. 2005).
Rituximab, however, appears more suited as a maintenance
therapy. It has minimal toxicity and requires infrequent dosing. In
the pivotal study the peak plasma concentration of rituximab
increased after each of the four infusions and the plasma
clearance correspondingly decreased from 38.2 mL/hour after 
the first infusion to 9.2 mL/hour after the fourth infusion
(McLaughlin et al. 1998). In 63% of patients rituximab was 
still detectable in the serum 3 months after the last 
infusion. Importantly, there was a significant positive 
correlation between median serum antibody levels and response
(Berinstein et al. 1998). Responders had a median serum
rituximab level of 25.4 mcg/mL compared with 5.9 mcg/mL in
nonresponders. This finding and the observation that in some
patients the duration of response to a second course of rituximab
may be longer than the duration of response to the first course 
of rituximab suggested that a prolonged course of rituximab may
improve response duration as well as improving remission rates
(Davis et al. 2000).Clinical evidence with rituximab maintenance
The results of randomized studies of rituximab as maintenance
therapy in follicular NHL are shown in Table 2. 
Rituximab maintenance after induction using single-agent
rituximab
In a phase II study, 62 patients with previously untreated indolent
NHL [small lymphocytic lymphoma (SLL) 39%, and FL 61%] 
received rituximab 375 mg/m2 per week intravenously for 
4 weeks (Hainsworth et al. 2002). A total of 77% were thought to
require some therapy by the treating physician. Responders and
those with stable disease (SD) at 6 weeks received repeated
courses at 6-month intervals for a maximum of four courses or
disease progression. At 6 weeks, responses were seen in 47%
(CR 7%, PR 40%) and SD was observed in 45% of patients after
induction. Fifty-eight percent went on to receive all four courses.
Maintenance rituximab increased the overall response rate (ORR)
to 73% with 37% achieving a CR. The median PFS was 
34 months, compared with the 23.5 months achieved with
rituximab induction alone in the study performed in asymptomatic
patients with low tumor burden described above (Colombat et 
al. 2001).
Subsequently, two randomized studies of rituximab maintenance
following standard rituximab induction have been reported
showing a PFS/event-free survival (EFS) benefit in the
maintenance arm. In the first study, performed by the Swiss
Group for Clinical Cancer Research (SAKK), Ghielmini et al. (2004)
treated 202 patients with chemotherapy-naïve (32%) or
relapsed/refractory (68%) FL. None of the patients had received
rituximab previously. In 185 evaluable patients the ORR at 
12 weeks was 52% (67% in chemotherapy-naïve and 46% in
previously treated patients) with a CR rate of 8%. One hundred
and fifty-one patients with CR, PR, or SD at 12 weeks were
randomized to no further treatment or prolonged treatment with
rituximab with one further infusion given at month 3, 5, 7, and 9.
There was a gradual decline in the ORR in the first group from
67% at 3 months to 44% at 12 months, and 28% at 24 months.
In the group receiving rituximab maintenance the ORR remained
stable initially (62% at 3 months and 66% at 12 months) before
declining at a slower rate to 45% at 24 months. The ORR was
only significantly different between the two groups beyond 1 year
(P=0.046). The CR rate in the maintenance group increased from
12% to 29% in the maintenance arm but CR rates also rose in the
control arm such that there was never a significant difference in
CR rates between the two arms. With a median follow-up of 
36 months the median EFS in the maintenance arm was almost
double that in the control arm (23.2 vs 11.8 months, P=0.024).
This was more marked when responders to rituximab induction
were considered separately (36 vs 16 months, P=0.004).
Conversely there was no significant difference in EFS between the
two arms when only those who achieved stable disease after
rituximab induction were analyzed (11 vs 8 months, P=0.35).
When only chemotherapy-naïve patients were considered, the
EFS was 36 vs 19 months (P=0.009). The median EFS of 3 years
which was achieved with induction using single-agent rituximab
followed by rituximab maintenance is comparable to the time to
treatment failure (TTF) achieved with induction therapy with
CHOP chemotherapy (30 months) (Hiddemann et al. 2005) or CVP
plus rituximab (R-CVP) chemoimmunotherapy (27 months)
(Marcus et al. 2005). Toxicity was acceptable with no increase in
infections in the rituximab maintenance group despite a
prolonged reduction in immunoglobulin M and B cell levels.
In the second study the primary endpoint was duration of
rituximab benefit. One hundred and fourteen previously treated
patients with FL and SLL received induction with four weekly
doses of rituximab 375 mg/m2 (Hainsworth et al. 2005). None of
the patients had received rituximab previously. Ninety patients
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Reference No. of patients Type of patients Median EFS/PFS
(maintenance vs
observation)
P value
Maintenance after induction with single-agent rituximab
Ghielmini et al. 2004 202 FL
Relapsed/refractory 68%
Treatment naïve 32%
All pts: 23.2 mo vs 11.8 mo
(naïve: 36 vs 19 mo)
P=0.024
(P=0.009)
Hainsworth et al. 2005 114 FL and SLL All pts: 31.3 mo vs 7.4 mo  P=0.007
Previously treated (FL only 31 mo vs 13 mo)
Maintenance after induction with chemotherapy alone
Hochster et al. 2005 237 FL 61 mo vs 15 mo  P=0.000003
Previously untreated
Maintenance after induction with chemotherapy with or without rituximab
van Oers et al. 2006 465 FL 51.5 mo vs 14.9 mo P<0.0001
Relapsed/refractory
Forstpointner et al. 2006 195 FL and mantle cell FL alone: response duration
not yet reached vs 26 mo 
P=0.035
Relapsed/refractory
Table 2 | Results of randomized studies of rituximab maintenance in follicular lymphoma
EFS, event-free survival; FL, follicular lymphoma; mo, month; PFS, progression-free survival; pts, patients; SLL, small lymphocytic lymphoma.125
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(78%) had an objective response (28%) or SD (51%) at 6 weeks
and were randomized to the maintenance arm with four weekly
doses of rituximab 375 mg/m2 every 6 months for a total of four
treatments, or the re-treatment arm where further four weekly
doses of rituximab were given only when disease progression was
noted. In the re-treatment arm further reinduction with rituximab
was allowed at subsequent episodes of disease progression
provided the preceding duration of response was greater than 
3 months. 
When considering the patients with FL alone, the initial ORR was
similar in each arm at 47% and 46%. Unlike the SAKK study the
best CR rate achieved was significantly better in the maintenance
arm (32% vs 7%). In common with the SAKK study, the median
PFS was significantly better in the maintenance arm (31 vs 
13 months). There was, however, no significant difference in
duration of rituximab benefit between the maintenance arm and
the re-treatment arm (31 vs 35 months). The re-treatment group
used 29% less rituximab than the maintenance group to achieve
this, which suggests an advantage for this group. However, at the
time of reporting, significantly more patients in the re-treatment
group remained on study (14 vs 4) and the disparity in rituximab
usage is likely to decrease with further follow-up. In addition, the
duration of rituximab benefit in the maintenance arm is likely to
have been underestimated as the duration of maintenance
therapy was limited in this arm but the number of re-treatment
courses was not limited in the re-treatment arm. In fact, a follow-
up study has shown that 33% of patients who progressed
following 2 years of maintenance obtained a further response with
single-agent rituximab while an additional 58% had stable
disease (Hainsworth et al. 2006). Although questions remain
about the validity of the primary endpoint, the benefit of rituximab
maintenance in terms of improved PFS is not in doubt.
Unfortunately, in common with the SAKK trial, there was no
assessment of the patients’ quality of life in this study. Hopefully
the ongoing Eastern Cooperative Oncology Group (ECOG) 4402
RESORT trial (Rituximab Extended Schedule Or Retreatment 
Trial) will conclusively answer whether the re-treatment or
maintenance results in a longer period of rituximab benefit. 
In this study previously untreated patients with low tumor 
burden, low-grade lymphomas will receive four doses of 
rituximab given at weekly intervals. Responders will be
randomized to either receive re-treatment with further courses of
rituximab (four doses given at weekly intervals) provided the time
to progression is more than 6 months, or maintenance rituximab
given as one infusion every 12 weeks until progression or 
unacceptable toxicity.
Rituximab maintenance after induction using chemotherapy
with or without rituximab
Further improvement in PFS was anticipated if rituximab
maintenance was administered after induction therapy using
chemotherapy or chemotherapy combined with rituximab. Three
randomized studies have now been published which confirm this
hypothesis; two studies were performed in previously treated
patients (Forstpointner et al. 2006; van Oers et al. 2006) and one
study in previously untreated patients (Hochster et al. 2005). 
In the European Organisation for Research and Treatment of
Cancer (EORTC) 20981 Intergroup study, 465 patients with
relapsed/refractory FL were reported (van Oers et al. 2006).
Patients had received a maximum of two nonanthracycline-
containing regimens prior to study entry (80% had received one
prior therapy), 16% had not responded to previous therapy, and
prior exposure to rituximab was not allowed. Seventy percent of
patients had an FL International Prognostic Index (FLIPI) score of
two or more at diagnosis (Solal-Celigny et al. 2004). The study
design involved two randomizations. Patients were initially
randomized to receive CHOP or rituximab plus CHOP (R-CHOP)
induction chemotherapy. Response was assessed after three
courses, patients with PD or SD went off-study, and responders
went on to receive a further three courses of induction therapy. 
A second randomization took place at completion of 
induction therapy between observation and maintenance
rituximab (administered once every 3 months for a maximum of 
2 years). The primary endpoint of the first randomization was
response while that of the second randomization was PFS. The
study was stopped early after a preplanned interim analysis
showed that both primary endpoints had been achieved.
Subgroup analysis, as requested by the independent data
monitoring committee, demonstrated benefit of maintenance
rituximab in the CHOP group but not in the R-CHOP group. It was
suggested that the trial be amended with all patients receiving 
R-CHOP induction followed by randomization to rituximab
maintenance or not. Recruitment was therefore suspended
pending a major protocol amendment. Meanwhile all data were
collected and a final analysis performed. This process took 
19 months by which time further follow-up was available for
analysis. At this analysis it was found that the primary question of
the amended protocol had already been answered and the trial
was not reopened. 
The ORR was significantly better in the group that received 
R-CHOP induction (85.1% vs 72.3%, P<0.0001), as was the CR
rate (29.5% vs 15.6%, P<0.0001); PR rates were similar (55.6%
vs 56.7%). With a median follow-up of 39.4 months from first
randomization there was a significant increase in median PFS in
the R-CHOP group (33.1 vs 20.2 months, P=0.003) without a
significant increase in OS at 3 years (82.5% vs 71.9%, P=0.096).
A total of 334 patients were randomized to receive maintenance
rituximab or not. With a median follow-up from second
randomization of 33.3 months, the median PFS was significantly
greater in the rituximab maintenance group (51.5 vs 14.9 months,
P<0.0001), equating to a gain of 3 years in PFS. A gain in PFS of
approximately 2.5 years was present whether patients received
CHOP induction (42.2 vs 11.6 months, P<0.0001) or R-CHOP
induction (51.8 vs 23 months P=0.0043), indicating that the
antilymphoma effect of rituximab is not exhausted during
induction. Importantly, rituximab maintenance was also found to
confer a significant OS benefit at 3 years when compared with
observation, with the risk of dying being reduced significantly
(85.1% vs 77.1%, P=0.0111). No breakdown of OS benefit
conferred by rituximab maintenance according to induction
regimen was given and therefore there is no evidence that
rituximab maintenance conferred a significant OS benefit
compared with observation if patients had received R-CHOP asinduction. The authors produced some data which indicate that
only a minority (41%) of patients in the observation arm received
rituximab as part of their first postprotocol treatment. Even
though this figure is higher than the 16% of patients in the
maintenance arm who received rituximab as part of their first
postprotocol treatment, the fact that many patients in the
observation arm did not receive rituximab with their next
treatment may account for some of the observed OS benefit for
patients in the maintenance arm.
Maintenance rituximab resulted in a nonsignificant increase in
grade 3 and 4 neutropenia (10.8% vs 5.4%), which probably
accounted for the significant increase in grade 3 and 4 infections
(mainly ear, nose, and throat infections) in this group (9% vs 2.4%,
P=0.009). Six of 167 patients withdrew from the maintenance arm
because of toxicity; four due to infection. 
It therefore appears that in patients with relapsed and refractory
FL, maintenance rituximab improves median PFS more than
three-fold when compared with observation. This is achieved with
minimal increase in toxicity. Even when rituximab maintenance
follows R-CHOP induction the median PFS is more than doubled.
The study also demonstrates an OS benefit at 3 years with
rituximab maintenance when patients who received R-CHOP and
CHOP induction are analyzed together. However this study
provides no evidence of a significant OS benefit attributable to
rituximab maintenance in the group who received R-CHOP
induction although the study was not designed to detect such 
a difference.
The German Lymphoma Study Group (GLSG) randomized
patients with relapsed/refractory FL and mantle cell lymphoma to
receive either FCM (fludarabine, cyclophosphamide,
mitoxantrone) or rituximab plus FCM (R-FCM) as induction
therapy (Forstpointner et al. 2006). Responders underwent a
second randomization to observation or to receive a course of
rituximab maintenance at 3 and 9 months. Each maintenance
course consisted of four weekly doses of rituximab. Patients who
had received prior rituximab were eligible but no information was
given regarding the number of patients who had received
rituximab prior to study entry. The first randomization was
stopped after 147 patients were recruited as R-FCM was found to
be superior in terms of response, response duration, and survival.
Subsequent patients all received R-FCM induction. Results of the
second randomization in the 81 patients with FL who received 
R-FCM induction demonstrated the benefit of rituximab
maintenance compared with observation. After a median follow-
up of 26 months the median response duration was 17 months in
the observation arm but had not been reached in the maintenance
arm (P=0.035). No survival difference has yet been observed 
(3-year OS 57% vs 77%, P=0.1). Infusion-related side effects
were noticed in 8% of maintenance cycles, generally mild or
moderate with only one patient requiring therapy to be
discontinued due to a severe allergic reaction.
Both the EORTC and GLSG studies recruited patients with
relapsed/refractory disease. In an ECOG study, 401 previously
untreated patients with FL or SLL were recruited and received
induction with six to eight cycles of CVP chemotherapy (Hochster
et al. 2005). Responders and patients with SD were randomized
to receive maintenance with four weekly doses of rituximab
administered every 6 months for a maximum of four courses 
(i.e. 2 years). Two hundred and thirty-seven patients with FL were
recruited, 64% of whom had high tumor burden and 37% had
high-risk disease according to the FLIPI. There was a highly
significant difference in 4-year PFS between the maintenance and
observation group (56% vs 33%, P=0.0000003), and the median
PFS was increased by almost 4 years in the maintenance group
(61 vs 15 months). This study also revealed an OS benefit with
rituximab maintenance at 4 years compared with observation
(88% vs 72%, P=0.03).
Unfortunately none of the randomized studies of maintenance
rituximab have measured patient-related quality of life. It is
generally assumed that a patient has a better quality of life if
periods of remission are prolonged; however, for some patients
repeated visits to receive therapy when they are otherwise well
can be a constant reminder of their disease and actually have a
significant negative impact on their quality of life. If rituximab is
given every 2 or 3 months the infusion can be given on the same
day as a scheduled follow-up visit thus minimizing the disruption
to the patient’s life.
Most patients now receive rituximab combined with
chemotherapy as first-line therapy and the value of maintenance
in this setting has not been demonstrated as yet. It is noteworthy
that CVP followed by rituximab maintenance in the ECOG study
yields a PFS almost twice the 33 months achieved by front-line 
R-CVP induction chemotherapy alone in the study by Marcus et
al. (2005). This suggests rituximab maintenance following R-CVP
in previously untreated patients with FL is likely to be of benefit,
however it must be noted that the proportion of patients with
high-risk FLIPI scores were different in the two studies (37% of
patients were high risk in the ECOG study compared with 45% in
the Marcus et al. study).
The value of rituximab maintenance following first-line therapy
with a rituximab chemotherapy combination will be answered
when the results of the PRIMA study are available. In this Groupe
d’Etude des Lymphomes de l’Adulte (GELA)-sponsored study,
which closed to recruitment in spring 2007, patients received a
choice of induction chemotherapy combined with rituximab, and
responders were then randomized to observation or maintenance
rituximab 375 mg/m2 given once every 2 months for a maximum
of 2 years. The primary endpoint is PFS. The single-arm MAXIMA
study is also currently recruiting patients who have had a
response to rituximab-containing induction therapy. These
patients, who may have had previous therapy, are allocated
rituximab 375 mg/m2 every 2 months for 2 years. The main aim is
to assess safety in a wider patient population.
Economic evidence and resource utilization
The standard therapeutic approach following induction of a
remission in patients with relapsed or refractory FL is either to
consolidate with high-dose therapy followed by ASCT or to keep
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the patient under observation and to re-treat when relapse of
disease progression occurs. Evidence for economic benefit, or
otherwise, of rituximab maintenance compared with either ASCT
or observation followed by re-treatment is very limited.
A Finnish study reported only in abstract form compared the
direct medical costs of ASCT to that of maintenance rituximab
(eight doses over 2 years) (Leppä et al. 2006). The cost of the
transplant was calculated to be €38600 while the cost of
maintenance rituximab was €19 700. ASCT resulted in a median
PFS of 34.1 months (n=12). When this was compared to the 
51.9 months achieved in the EORTC 20981 study, rituximab
maintenance was shown to improve PFS by 17.8 months. On the
basis of this limited data the authors concluded that improved
PFS with cost savings may be achieved with the use of rituximab
maintenance rather than ASCT. Clearly the characteristics of the
patients who underwent ASCT need to be comparable to those
recruited into the EORTC study for this comparison to be valid
and it is not clear that this was the case. In the CUP study
(Schouten et al. 2003), which demonstrated the benefit of ASCT
compared with observation in patients with relapsed FL (not
refractory patients), the median PFS had not been reached with a
follow-up of 69 months. Clearly, if the PFS for ASCT had been
based on this study the outcome may have been different.
Maturi et al. (2006) developed a pharmacoeconomic model based
on the EORTC data and quality-of-life data obtained by
questionnaire from 165 patients with FL not included in the
EORTC study. According to this analysis the incremental cost-
effectiveness ratio of rituximab maintenance versus observation
alone was estimated at $Can20428 per quality-adjusted 
life-year gained.
In the study by Hainsworth et al. (2005) no significant difference 
in the duration of the period of rituximab benefit was noted 
when maintenance was compared with re-treatment. 
Re-treatment used 29% less rituximab compared with
maintenance. This study did have some shortcomings 
as mentioned earlier and no consideration was given to the
patients’ quality of life.
Patient group/population
Rituximab maintenance in patients with relapsed and refractory
FL only appears to benefit patients who respond to induction
therapy. In the SAKK study, only responders to single-agent
rituximab at 12 weeks benefited; those with SD following
induction did not. In the study by Hainsworth et al. (2005) there
was no analysis of the benefit of rituximab maintenance
according to the response (CR/PR vs SD) to rituximab induction.
In the EORTC and GLSG studies only responders to induction
therapy were eligible for randomization to maintenance; in the
EORTC study both patients who achieved a CR and those who
achieved a PR to induction therapy had a significantly improved
PFS with maintenance therapy.
Rituximab maintenance following first-line chemotherapy
combined with rituximab is widely expected to result in a
significant benefit for patients in terms of PFS but, as yet, this
remains unproven.
Dosage, administration, and formulation
Rituximab is available in 100 mg concentrate in 10 mL for
intravenous infusion. The recommended dose of rituximab used
as a single agent for adult patients with FL is 375 mg/m2 body
surface area, administered as an intravenous infusion once
weekly for 4 weeks. The recommended dosage of rituximab in
combination with CVP chemotherapy for adults with FL is 
375 mg/m2 for eight cycles (21 days/cycle), administered on 
day 1 of each chemotherapy cycle. Premedication consisting of
an antipyretic and an antihistamine [e.g. acetaminophen
(paracetamol) and diphenhydramine] should always be
administered before each infusion of rituximab, and
premedication with glucocorticoids should also be considered.
Patients should be closely monitored.
Place in therapy
There is clear evidence from randomized studies that rituximab
maintenance prolongs PFS substantially in patients with
relapsed/refractory FL who are rituximab naïve and respond to
reinduction therapy with either single-agent rituximab, CHOP
chemotherapy with or without rituximab, or FCM with rituximab.
There is also evidence from one randomized study that rituximab
maintenance prolongs PFS and OS in previously untreated
patients who do not progress following induction with CVP
chemotherapy (without rituximab). It is not clear whether patients
with SD after CVP have a significant improvement in PFS and OS.
There is substantial evidence from one randomized study
indicating that rituximab maintenance significantly improves EFS
in previously untreated patients who receive single-agent
rituximab as induction therapy. There is moderate evidence that
rituximab maintenance improved OS in a group of patients with
relapsed/refractory FL who were rituximab naïve and who
responded to reinduction with a combination of either CHOP
chemotherapy with rituximab or CHOP chemotherapy alone.
There is however currently no evidence from randomized studies
that unequivocally demonstrates an OS benefit from rituximab
maintenance in patients with relapsed/refractory FL who receive
only rituximab-containing chemotherapy at reinduction.
There is moderate evidence to suggest that in patients with
relapsed/refractory FL, re-treatment with rituximab at disease
progression may confer a similar period of rituximab benefit as
rituximab maintenance.
There is currently no evidence from randomized studies that
clearly demonstrates the benefit of rituximab maintenance in
patients with relapsed/refractory FL who have been exposed to
rituximab prior to relapse, in previously untreated patients with FL
who receive chemotherapy and rituximab as induction therapy, or
for an improvement in patients’ quality of life.
Taken together, currently the place of rituximab maintenance in
the therapy of FL appears to be in two main groups of patients.Firstly, a dwindling group of patients with relapsed/refractory
disease who have not received rituximab previously and who are
not suitable for or who do not wish to undergo ASCT. This group
will get smaller and smaller as more patients receive 
rituximab chemotherapy combinations as first-line therapy. 
The large improvement in PFS seen with rituximab 
maintenance may be comparable to that achieved in the 
same patient population following consolidation therapy with
ASCT. Whether one treatment is superior can only really be
determined by further randomized studies. The results of 
such studies, if they take place, may soon become obsolete 
if the place of rituximab maintenance is found to be in a 
first remission following first-line therapy with rituximab 
chemotherapy combinations. 
The second group includes patients who receive first-line
therapy using chemotherapy without rituximab. Now that
rituximab is widely available and rituximab chemotherapy
combinations have been shown to be superior to chemotherapy
alone as induction therapy, patients are unlikely to be treated in
this way.
Many different schedules of rituximab maintenance have been
used. It is not clear which schedule is optimal. Gordan et 
al. (2005) treated patients with rituximab 375 mg/m2 weekly 
for 4 weeks. Further rituximab was administered only when 
the plasma concentration fell below 25 mcg/mL (a level 
which correlated with response in a previous study). The 
median time to the next infusion to achieve this was 
2–5 months, with 50% of patients achieving this level with 
a dosing interval of 3 months and almost all with a dosing 
interval of 2 months. This suggests that 2–3 monthly dosing is
probably optimal. 
The duration of maintenance is also uncertain. Further rituximab
benefit has been noticed even after 2 years. However it is worth
bearing in mind that in patients with low tumor burden who
received rituximab 375 mg/m2 weekly for 4 weeks, 24% of
responders maintained their response at 5 years and 15% at 
7 years without any further therapy (Colombat et al. 2006). 
Of course, the longer the maintenance period the greater 
the financial cost as well as the possibility that continued 
B-cell depletion will result in significant adverse effects. The
SAKK is currently running a study comparing two different
schedules of rituximab maintenance in patients with untreated,
relapsed, or refractory FL. After standard single-agent 
rituximab 375 mg/m2 induction patients will be randomized 
to receive either one dose of rituximab 375 mg/m2 every 
2 months on four occasions, or every 2 months for 5 years or 
until relapse, progression, or unacceptable toxicity. This 
study should give a greater insight into the adverse effects of
rituximab maintenance. 
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